Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (September 2021)
24 slides from Anatara Lifesciences's investor presentation, Sep 6, 2021
Slide 1: ASX Release
ASX Release Anatara Investor Presentation MELBOURNE, 6 September 2021: Anatara Lifesciences (ASX: ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven
Slide 2: Investor Presentation September 2021
Investor Presentation SEPTEMBER 2021 ---------------- ASX: ANR
Slide 3: Developing the next generation of gastrointestinal health products
Developing the next generation of gastrointestinal health products • More than ever, the world is looking for safe and effective solutions for gastrointestinal tract (GIT or ‘gut’) symptoms and disorders • 40% of global consumers say digestive complaints have had some influence on their lives 1 • Ir
Slide 4: Global consumer health market opportunity in managing gastrointestinal tract symptoms
Global consumer health market opportunity in managing gastrointestinal tract (GIT or ‘gut’) symptoms and general wellbeing is enormous >US$8 billion spend on OTC and digestive remedies alone 2,3 >US $1 billion market in IBS alone 4 Probiotic supplements Other GI supplements OTC digestive supplements
Slide 5: Key Management & Board of Directors
Key Management & Board of Directors Steve Lydeamore, CEO Dr David Brookes, Chair • 25+ years international pharmaceutical experience in • 30+ years international experience in the health and Australia, USA and Canada biotechnology industries • Lead roles in global business development, manufacturing
Slide 6: Building a Health Portfolio
Building a Health Portfolio • Anatara aims to be the ‘go to’ company for gut health solutions, including treatments, diagnostics and advice • Focused on delivering evidence-based treatments and solutions for GIT health needs GaRP Technology to provide a pipeline of products • Potential to apply our
Slide 7: GaRP technology
GaRP technology A potential break though for gut health Unique knowledge of Ingredients are Well-characterised Synergistic effects Gut-Brain bromelain’s ‘fingerprint’ GRAS proprietary mix Connection Formulation Function within formulation and potential impact on symptoms Component Restores Influence
Slide 8: Grounded in scientific evidence
Grounded in scientific evidence Leaky ‘tight junctions’ allow pathogens Increase in mucin gene expression to Restored ‘tight junctions’ allow the body to enter the body causing harm promote mucosal healing to resist pathogens and entry of toxins Successful Proof of Concept Studies (February 2019). D
Slide 9: Human Health
Human Health GaRP pipeline progressing towards commercialisation • GaRP and 3FDC (3 components with functional delivery coating) – All components GRAS (FDA: generally regarded as safe) – Patent pending formulation with functional coatings of synergistic combination of components • Ethics approved cl
Slide 10: IBS and IBD in a minute
IBS and IBD in a minute 11% IBS affects around 11% of the global population 6 >5m With accelerating incidence, IBD has an estimated >5million sufferers worldwide 7 • Patients experience symptoms such as • Up to 50% of IBS/IBD patients turn to pain, bloating and diarrhoea dietary supplements, complem
Slide 11: GaRP: One product, multiple benefits
GaRP One product, multiple benefits Scientifically designed to manage and control background IBS symptoms as well as episodic flare ups Designed as an everyday option to manage the causes and relieve symptoms of IBS such as pain, cramping, gas, bloating, diarrhoea and/or constipation Coated componen
Slide 12: Clinical trial – Irritable Bowel Syndrome (IBS-D)
Clinical trial – Irritable Bowel Syndrome (diarrhoea subtype; IBS-D) Title: Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS-D patients: A Randomized, Double-blind, Placebo controlled virtual clinical trial Population: Males and female
Slide 13: Depression, Anxiety, Stress in a minute
Depression, Anxiety, Stress in a minute 19% 38% 19% of Americans have 38.2% of the EU population met the an anxiety disorder in criteria for a psychiatric disorder, <1/3 any given year 14 received treatment for it 15 • 19% of Americans have an anxiety • 24% of U.S. adults with a mental illness repor
Slide 14: 3FDC Positively Influencing the Gut-Brain Connection
3FDC Positively Influencing the Gut-Brain Connection Aims to assist homeostasis of the “gut” to promote overall health and wellbeing Targeting modulation of psychobiological processes driving anxiety-related disorders Coated components released in the large intestine (colon) to positively influence
Slide 15: What is the gut-brain connection?
Adapted from Blood Brain Barrier What is the gut-brain connection? 18 • The gastrointestinal system offers an integrated interface for regulation of various body functions in health and disease. • The lining of the gut, known as the epithelium, is also the first line of defence against pathogens tak
Slide 16: Clinical trial – Psychological functioning
Clinical trial – Psychological functioning Title: The effects of 3FDC dietary supplementation on psychological functioning in an adult population Population: ~100 males or females 18-55 years of age with with moderate levels of depression, anxiety, or stress symptoms indicated by the Depression, Anx
Slide 17: Animal Health
Animal Health Portfolio progressing towards commercialisation • Detach®, ANR-pf and BONIFF – Orally administered, non-antibiotic products – Natural products extracted from pineapple stems – Unlike antibiotics and zinc oxide, unlikely to contribute to antimicrobial resistance • Medicinal use of zinc
Slide 18: Achievements and near term milestones
Achievements and near term milestones Human health assets Animal health assets Achievements Achievements • All components GRAS (FDA: generally regarded as safe) • ANR-pf: challenge trial in poultry for subclinical and necrotic • Patent pending formulation with functional coatings of synergistic ente
Slide 19: Commercialisation Strategy for GaRP Pipeline including 3FDC
Commercialisation Strategy for GaRP Pipeline including 3FDC GaRP is a potential breakthrough, evidence based product • targeting the cause of IBS, not just a product that Huge underlying demand given IBS prevalence across key markets treats symptoms 2 3 Key markets • North America, Europe, select As
Slide 20: Licensing discussion progress and portfolio diversification
Licensing discussion progress and portfolio diversification Anatara is progressing licensing discussions with international consumer health companies for GaRP and evaluating approach • ‘Local Hero’ licensing approach – forming partnerships with regional leaders in 'gut' health taking advantage of lo
Slide 21: Program pipeline
Program pipeline PRECLINICAL CLINICAL COMMERCIAL PROGRAM DELIVERY DISCOVERY REGISTRATION In-Vivo Proof of RIGHTS In-Vitro Pivotal (animal) Concept Scour (diarrhoea) Oral Detach® Piglets ✓ ✓ ✓ ✓ ✓ Australia (APVMA) Global Drench Oral ANIMAL BONIFF Piglets ✓ ✓ ✓ ✓ Global In-feed Subclinical & Clinical
Slide 22: Glossary
Glossary IBS Irritable bowel syndrome (IBS) is a condition that affects the colon (large bowel). Key symptoms include abdominal pain or discomfort, stomach bloating, chronic diarrhoea or constipation, or alternating between the two. IBD Inflammatory bowel diseases are conditions in which the lining
Slide 23: Disclaimer
Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company).
Slide 24: Contact Anatara Lifesciences Ltd
Contact Anatara Lifesciences Ltd Steven Lydeamore, Chief Executive Officer +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — Investor Presentation (September 2021) on 6ix